Zobrazeno 41 - 50
of 186
pro vyhledávání: ''
Autor:
John D. Minna, David C.L. Lam
Publikováno v:
Cancer Prevention Research. 4:1724-1727
Nicotine replacement therapy (NRT) is a valuable, proven, and U.S. Food and Drug Administration-approved tool for smoking cessation. However, the discoveries of functional nicotinic acetylcholine receptors (nAChR) on lung epithelial and cancer cells
Publikováno v:
Cancer Prevention Research. 4:779-782
The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study a
Autor:
Peter L. Choyke, Liqiang Xi, Jeremy Force, Corrine Keen, Mark Raffeld, Martin Gutierrez, Ariel Lopez-Chavez, Baris Turkbey, Liang Cao, Ronan J. Kelly, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Yunkai Yu, Arun Rajan, Giuseppe Giaccone
Publikováno v:
Clinical Cancer Research. 17:1190-1199
Purpose: Sorafenib, a multikinase inhibitor targeting Raf and VEGFR, has shown activity in unselected patients with non–small-cell lung cancer (NSCLC). At present there are no validated biomarkers indicative of sorafenib activity. Experimental Desi
Autor:
Mariano Provencio, Charles L. Sawyers, Bartomeu Massuti, Felipe Cardenal, Sara Simonetti, Itziar de Aguirre, Susana Benlloch, Cristina Queralt, Miquel Taron, Rosario García-Campelo, R. Porta, Jose Miguel Sanchez, Trever G. Bivona, Carlota Costa, Clara Mayo, Dolores Isla, Miguel Angel Molina, Noemi Reguart, Aurelio Ariza, Santiago Viteri, Margarita Majem, Jordi Bertran-Alamillo, Enric Carcereny, Jose Javier Sanchez, Jose Luis Mate, Maria Sanchez-Ronco, Manuel Cobo, A. Insa, Anna Gimenez-Capitan, Pedro Mendez, Teresa Moran, Rafael Rosell
Publikováno v:
CLINICAL CANCER RESEARCH
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Purpose: Advanced non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib. However,
Autor:
Jing Pan, Ronald A. Lubet, Pengyuan Liu, Ming You, Da-Ren Chen, Jingjie Zhang, Ruth Chen, Qi Zhang, Yian Wang
Publikováno v:
Cancer Prevention Research. 4:270-276
Prior studies have shown the retinoid X receptor (RXR) agonist bexarotene has preventive efficacy in rodent models of mammary and lung tumorigenesis albeit causing hypertriglyceridemia and hypercholesterolemia. We reasoned that bexarotene delivered b
Publikováno v:
Cancer Research. 78:1142-1142
Lung adenocarcinoma (LUAD), the most common histological subtype of lung cancer, remains one of the leading causes of cancer-related deaths worldwide. With improving knowledge in the molecular aberrations underlying lung carcinogenesis, a large numbe
Autor:
Hossein Borghaei, Kathy Q. Cai, Vladimir Khazak, Mark A. Hitrik, Peter Makhov, Anna S. Nikonova, Rohan Brebion, Ilya G. Serebriiskii, Yanis Boumber, Brian L. Egleston, Eleanor Avril, Erica A. Golemis, Emmanuelle Nicolas, Alexander E. Kudinov, Alexander Y. Deneka
Publikováno v:
Cancer Research. 78:4452-4452
Musashi-2 (MSI2) is an RNA-binding protein that regulates mRNA translation. We recently established that MSI2 is elevated in a subset of non-small cell lung cancer (NSCLC) tumors upon progression and drives NSCLC metastasis, in part based on activity
Publikováno v:
Cancer Research. 78:2156-2156
A mechanism underlying anti-cancer drug resistance relies on the existence of cancer stem cells (CSCs). However, CSCs are either absent or are few in number in xenograft tumors and syngeneic mouse models. We developed new lung cancer mouse models wit
Publikováno v:
Cancer Research. 78:5099-5099
Background: Lung cancer is the deadliest malignancy in the United States. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, and is frequently driven by activating mutations in the gene encoding the KRAS GTPase (e.g. KRASG12D). Our previou
Publikováno v:
Cancer Research. 78:894-894
Non-small cell lung cancer (NSCLC) is a major type of lung cancer which accounts for approximately 80-85% of all lung cancers. Epidermal growth factor receptor (EGFR)- targeted tyrosine kinase inhibitors (TKIs), such as gefitinib have improved the su